2021 Managed Healthcare Executive® Pharmacy Survey: Lasting Effects of the Pandemic
In this part two series, participants give their opinions on the lasting effects of the pandemic. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next several days.
The pandemic flipped the switch on telehealth and at-home care, and the respondents to our annual Pharmacy Survey see them as having staying power. A quarter of the respondents said the increased use of telehealth will be the most important, lasting effect of the pandemic on the U.S. healthcare system and 35% put at-home care of all kinds in that category. Although many experts see the pandemic as accelerating the adoption of value-based payment, only 4% of our respondents ranked that as the pandemic’s most important lasting effect.
Not surprisingly, an increase in research and development on infectious disease got the most votes for the important, lasting effect on the pharmaceutical sector.
The online survey was conducted from April 5 through May 10.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
A Renewed Commitment to HIV Vaccine Development Despite Advancements in Antiretrovirals | AIDS 2024
July 25th 2024The HIV vaccine field has recently faced setbacks with trials like PrepVacc, Mosaico and Imbokodo ending early due to lack of preventive efficacy. Although there have been challenges, scientists have made discoveries showing that the immune system can be prepared to fight HIV with special antibodies.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
ViiV Healthcare Will Not Continue Trials of Subcutaneous Cabenuva | AIDS 2024
July 25th 2024A substudy of the FLAIR phase 3 trial found that participants favored intramuscular injection of Cabenuva over the subcutaneous version due to pain and the development of nodules and reddening of the skin.
Read More
